ethyl 5-phthalimidopentimidate hydrochloride | 86649-65-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: ethyl 5-phthalimidopentimidate hydrochloride
• 英文别名: Ethyl 5-(1,3-dioxoisoindol-2-yl)pentanimidate;hydrochloride
• CAS: 86649-65-2
• 化学式: C₁₅H₁₈N₂O₃*ClH
• 分子量: 310.78
• InChiKey: XGCYOHLFVKYRCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.89
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  70.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(乙基氨基)异烟酰肼 、 ethyl 5-phthalimidopentimidate hydrochloride 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 16.0h， 生成 3-(3-phthalimidobutyl)-5-<2-(ethylamino)-4-pyridyl>-1,2,4-triazole
  参考文献：
  名称：

  Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists

  摘要：

  The structural relationship of the competitive histamine H2-receptor antagonist 3-amino-5-(2-amino-4-pyridyl)-1,2,4-triazole (1) to the agonist histamine and to antagonists of the cimetidine type was explored by the design and synthesis of four series of bioisosterically designed prototypes. Biological data from these series was best interpreted as indicating a similarity between the imidazole moiety of histamine and cimetidine and the 2-amino-4-pyridyl moiety of 1. On the basis of this data, sequential replacement of 2-amino-4-pyridyl by 2-[(dimethylamino)methyl]-5-furyl and 2-guanidino-4-triazolyl moieties led to a structurally more potent series of biaryl histamine H2-receptor antagonists. The best of these, 2-methyl-4-(2-guanidino-4-thiazolyl)imidazole (29, CP-57,361-1) was 120 times more potent as a histamine H2-receptor antagonist than 1.

  DOI：

  10.1021/jm00161a005

文献信息

• [EN] INHIBITORS OF SYK<br/>[FR] INHIBITEURS DE SYK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014060371A1

  公开（公告）日：2014-04-24

  The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式I的新化合物，其中所有变量取代基如本文所述定义，这些化合物是SYK抑制剂，可用于治疗自身免疫性和炎症性疾病。
• INHIBITORS OF SYK
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150284367A1

  公开（公告）日：2015-10-08

  The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式I的新化合物：其中所有可变取代基如本文所述，它们是SYK抑制剂，用于治疗自身免疫和炎症性疾病。
• Inhibitors of SYK
  申请人：Hoffmann-La Roche Inc.

  公开号：US10112928B2

  公开（公告）日：2018-10-30

  The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及式 I 的新型化合物的用途：其中所有可变取代基的定义如本文所述，它们是 SYK 抑制剂，可用于治疗自身免疫性和炎症性疾病。
• LIPINSKI C. A.; LAMATTINA J. L.; OATES P. J., J. MED. CHEM., 29,(1986) N 11, 2154-2163
  作者：LIPINSKI C. A.、 LAMATTINA J. L.、 OATES P. J.

  DOI：——

  日期：——
• EP2909174A1
  申请人：——

  公开号：EP2909174A1

  公开（公告）日：2015-08-26